Request Demo
Last update 16 Sep 2025
BZE-2204
Last update 16 Sep 2025
Overview
Basic Info
Drug Type CAR-T |
Synonyms CD19/CD22/BCMA CAR-T(Shanghai Cell Therapy Group), BZE 2204, BZE2204 |
Target |
Action inhibitors |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors), CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD22 inhibitors(CD22 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with BZE-2204NCT07174843
An Exploratory Clinical Study to Evaluate the Safety and Efficacy of BZE2204 CD19/CD22/BCMA CAR-T Cells in Subjects With Relapsed or Refractory Active Autoimmune Diseases
NCT06732232
A Dose Escalating Study of CD19/CD22/BCMA Three Targets Autologous Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Subjects With Relapsed/Refractory Multiple Myeloma
NCT06446128
A Dose Escalating Study of CD19/CD22/BCMA Three Targets Autologous Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)
100 Clinical Results associated with BZE-2204
Login to view more data
100 Translational Medicine associated with BZE-2204
Login to view more data
100 Patents (Medical) associated with BZE-2204
Login to view more data
100 Deals associated with BZE-2204
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Idiopathic Inflammatory Myopathies | Phase 1 | China | 01 Sep 2025 | |
| Lupus Nephritis | Phase 1 | China | 01 Sep 2025 | |
| Purpura, Thrombocytopenic, Idiopathic | Phase 1 | China | 01 Sep 2025 | |
| Relapse multiple myeloma | Phase 1 | China | 12 Dec 2024 | |
| B-cell lymphoma refractory | Phase 1 | China | 07 May 2024 | |
| Non-Hodgkin Lymphoma | Preclinical | United States | 28 Apr 2025 |
Login to view more data
Clinical Result
Clinical Result
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free